| Product Specific References | Ber-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H. Blood. 74: 1678-1689, 1989. CD30 expression in non-Hodgkin's lymphoma. Piris M, Brown DC, Gatter KC, Mason DY. Histopathology 17:211-218, 1990. Assignment of the human CD30 (Ki-1) gene to 1p36. Fonatsch C, Latza U, Durkop H, Rieder H, Stein H.enomics 14:825-826, 1992. CD30 expression in follicular lymphoma. Gardner LJ, Polski JM, Evans HL, Perkins SL, Dunphy CH. Arch Pathol Lab Med. 125:1036-1041, 2001. Aggressive Epstein-Barr virus-associated, CD8+, CD30+, CD56+, surface CD3- natural killer (NK)-like cytotoxic T-cell lymphoma. Tao J, Shelat SG, Jaffe ES, Bagg A. Am J Surg Pathol. 26:111-118, 2002. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, Filippa DA, Nimer SD, Teruya-Feldstein J. Hum Pathol. 33:968-974, 2002. Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression. George DH, Scheithauer BW, Aker FV, Kurtin PJ, Burger PC, Cameselle-Teijeiro J, McLendon RE, Parisi JE, Paulus W, Roggendorf W, Sotelo C. Am J Surg Pathol. 27:487-493, 2003. |
|---|